EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metabolic dysfunction and insulin resistance in depression: mechanisms, evidence, and therapeutic implications

Katerina Palacek, Olivier Corbeil, Saguna Katyal, Gabriele Lo Buglio, Carl Zhou, Stanley Wong, Nicholas Fabiano

Frontiers in Psychiatry · 20.08.2026 · 17

DOI: 10.3389/fpsyt.2026.1930167 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Psychiatry, online erschienen am 20.08.2026. Verfasst von Katerina Palacek und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major depressive disorder (MDD) remains one of the most frequently diagnosed mental health disorders and a leading cause of disability worldwide. The discovery of new treatments for MDD is necessary given up to 30% of individuals with MDD are resistant to current antidepressant treatments. The significant physiological interplay between MDD and metabolic conditions is crucial to consider for future therapeutics given the current obesity epidemic and the increased prevalence of treatment-resistant depression in individuals with metabolic dysfunction. The aim of this review is to discuss the relationship between metabolic dysfunction and MDD, while highlighting the potential antidepressant effects of insulin. There are interconnected perpetuating cycles involving hypothalamic-pituitary-adrenal (HPA) axis dysfunction, inflammation, obesity, insulin resistance, and MDD. Evidence on the efficacy of agents that target insulin resistance for depression is mixed and mechanisms by which these agents may improve depressive symptoms have not been clearly elucidated in studies reporting benefit. While there is a clear need to continue research on treatments that address the burden imposed by treatment-resistant depression, current data on whether insulin-sensitivity-targeting therapies can fill this gap remain limited. Clinically, routine metabolic screening in MDD could guide precision treatments targeting insulin pathways, particularly in those with metabolic dysfunction. Future studies considering the role of insulin, especially in those with insulin resistance, may enable development of novel therapeutics.

Schlagwörter

Stichwörter der Autor:innen

GLP- 1 receptor agonistsMDDdepressionglucoseinsulinmajor depressive disorder (MDD)metforminmood

Autor:innen und Institutionen

  • Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.
  • Ottawa Hospital Research Institute (OHRI), Clinical Epidemiology Program, University of Ottawa, Ottawa, ON, Canada.
  • Department of Pharmacy, Quebec Mental Health University Institute, Quebec, QC, Canada.
  • University of Ottawa, School of Epidemiology and Public Health, Ottawa, ON, Canada.
  • Ottawa Hospital Research Institute (OHRI), Neuroscience Program, University of Ottawa, Ottawa, ON, Canada.

Zitieren

APA

Palacek, K., Corbeil, O., Katyal, S., Lo Buglio, G., Zhou, C., Wong, S., & Fabiano, N. (2026). Metabolic dysfunction and insulin resistance in depression: mechanisms, evidence, and therapeutic implications. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1930167

Vancouver

Palacek K, Corbeil O, Katyal S, Lo Buglio G, Zhou C, Wong S, et al. Metabolic dysfunction and insulin resistance in depression: mechanisms, evidence, and therapeutic implications. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1930167

BibTeX
@article{Palacek2026,
  author = {Palacek, Katerina and Corbeil, Olivier and Katyal, Saguna and Lo Buglio, Gabriele and Zhou, Carl and Wong, Stanley and Fabiano, Nicholas},
  title = {Metabolic dysfunction and insulin resistance in depression: mechanisms, evidence, and therapeutic implications},
  journal = {Frontiers in Psychiatry},
  year = {2026},
  volume = {17},
  doi = {10.3389/fpsyt.2026.1930167}
}
Kostenlos starten →